Hemorrhagic Disease of the Newborn

HEMORRHAGIC DISEASE OF THE NEWBORN (HDN)

  • Hemorrhagic disease is a bleeding disorder that may occur during the first few days of life.

  • In healthy neonates:

    • Prothrombin time (PT) and activated partial thromboplastin time (aPTT) are naturally longer than in adults due to the immaturity of the coagulation system.

    • Despite these prolonged coagulation times, healthy newborns do not have an increased risk of spontaneous bleeding.

CAUSES OF HEMORRHAGIC DISEASE IN NEWBORN

  • Coagulation Factor Abnormalities:

    • Congenital or acquired deficiencies of clotting factors, primarily linked to Vitamin K Deficiency Bleeding, and inherited disorders like hemophilia or consumptive coagulopathies.

  • Platelet Abnormalities:

    • Include quantitative defects (neonatal thrombocytopenia) and qualitative platelet dysfunction, impairing primary hemostasis.

  • Fibrinolytic System Disturbances:

    • Excessive fibrinolytic activity results in accelerated degradation of fibrin clots, leading to failure of stable clot formation.

  • Vascular Disorders:

    • Abnormalities in the vascular wall or endothelial integrity cause increased capillary fragility and bleeding propensity.

  • Other or Multifactorial Conditions:

    • Systemic diseases, metabolic derangements, or combined hemostatic defects disrupting the balance of neonatal hemostasis.

CLASSIFICATION OF NEONATAL HEMORRHAGIC DISORDERS

  • Inherited Hemorrhagic Disorders:

    • Hemophilia A – deficiency of coagulation factor VIII

    • Hemophilia B – deficiency of coagulation factor IX

    • Von Willebrand Disease – defect of von Willebrand factor affecting platelet adhesion and factor VIII stability

    • Congenital deficiencies of other coagulation factors (e.g., factors II, V, VII, X, XI, XIII)

    • Congenital platelet function disorders (e.g., Glanzmann Thrombasthenia)

  • Acquired Hemorrhagic Disorders:

    • Vitamin K Deficiency Bleeding (Hemorrhagic disease of the newborn)

    • Disseminated Intravascular Coagulation

    • Neonatal Thrombocytopenia

    • Liver dysfunction affecting clotting factor synthesis

    • Sepsis-associated coagulopathy

    • Drug-induced or maternal antibody-mediated platelet disorders

HEMOPHILIA

  • Hemophilia is a hereditary coagulation disorder characterized by a deficiency or dysfunction of specific clotting factors, leading to impaired hemostasis and a prolonged bleeding tendency.

  • In neonates with hemophilia, bleeding may be prolonged or difficult to control due to inadequate levels of essential coagulation factors in circulation.

HEMOPHILIA A, B, C

Feature

Hemophilia A

Hemophilia B

Hemophilia C

Deficient factor

Factor VIII

Factor IX

Factor XI

Other name

Classic hemophilia

Christmas disease

Factor XI deficiency

Inheritance

X-linked recessive

X-linked recessive

Usually autosomal recessive

Frequency

Most common (80-85%)

Less common (15-20%)

Rare

Clinical severity

Variable: mild, moderate, severe

Similar spectrum to Hemophilia A

Usually mild bleeding tendency

Typical manifestations

Prolonged bleeding, hemarthrosis, deep tissue hemorrhage

Similar to Hemophilia A

Mild bleeding, often after surgery or trauma

CLINICAL MANIFESTATIONS OF HEMOPHILIA

  • The clinical presentation is primarily characterized by recurrent or prolonged bleeding episodes resulting from impaired coagulation.

    • Severity and frequency of symptoms generally correlate with the level of clotting factor deficiency.

    • Hemarthrosis

    • Recurrent bleeding into joints, especially knees, ankles, and elbows, leading to pain, swelling, and progressive joint damage.

    • Cutaneous Bleeding

    • Manifests as ecchymoses and easy bruising due to bleeding into skin and subcutaneous tissues.

    • Intramuscular and Soft Tissue Hemorrhage

    • Results in formation of deep hematomas, which may cause pain, swelling, and occasionally neurovascular compression.

    • Mucosal Bleeding

    • Includes bleeding from oral cavity, nasal mucosa (epistaxis), and gingiva.

    • Prolonged bleeding following dental procedures or tooth loss reflects impaired clot formation.

    • Hematuria and Gastrointestinal Bleeding

    • Evidenced by blood in the urine or stool.

    • In contrast, Hemophilia C generally presents as milder and may remain asymptomatic; however, excessive bleeding may occur following surgical procedures or significant trauma.

DIAGNOSIS OF HEMOPHILIA

  • Diagnosis established through detailed family history, clinical evaluation, and specialized laboratory investigations:

    • Positive family history of bleeding disorders, especially in male relatives, raises suspicion due to the X-linked inheritance.

    • Laboratory Investigations:

    • Complete Blood Count (CBC): Evaluates RBCs, WBCs, platelet count, hemoglobin concentration, hematocrit levels. Normal platelet counts are noted in hemophilia but helps exclude other disorders.

    • Coagulation Factor Assays: Quantitative measurement of factors, particularly factor VIII and IX, to confirm Hemophilia A or B.

    • Bleeding time/platelet function tests: Evaluate primary hemostasis and the efficiency of platelet-mediated clot formation.

    • Genetic (DNA) Testing: Identifies mutations in genes encoding coagulation factors, confirms diagnosis, determines carrier status, and provides genetic counseling.

MANAGEMENT OF HEMOPHILIA

  • The primary goal is to prevent and control bleeding episodes, particularly intracranial hemorrhage and hemarthroses, as serious complications.

  • Joint Bleeding (Hemarthrosis):

    • Acute immobilization may be necessary to limit joint damage.

    • In severe or recurrent cases, surgical interventions (synovectomy or joint replacement) may be required.

    • Rehabilitation includes physical therapy and targeted exercises to maintain mobility and strengthen musculature.

  • Severe Blood Loss:

    • Requires blood transfusions or replacement therapy with specific clotting factor concentrates to restore hemostasis.

  • Prophylactic Factor Replacement:

    • Regular administration of deficient clotting factor (factor VIII or IX) prevents spontaneous bleeding and protects joints, particularly in children with severe disease.

  • Adjunctive Measures:

    • Pain management, trauma avoidance, and education regarding early recognition of bleeding episodes.

VON WILLEBRAND DISEASE (VWD)

  • VWD is an inherited bleeding disorder caused by quantitative or qualitative defects of von Willebrand factor (VWF), a critical glycoprotein in hemostasis.

    • VWF mediates platelet adhesion to subendothelial collagen at sites of vascular injury and serves as a carrier and stabilizer for factor VIII, facilitating platelet-fibrin clot formation.

    • VWD is the most common inherited bleeding disorder worldwide.

    • The disorder is autosomal in inheritance, caused by mutations on chromosome 12 and affects males and females equally.

CLINICAL MANIFESTATIONS OF VON WILLEBRAND DISEASE (VWD)

  • Clinical features reflect defective platelet adhesion and secondary deficiency of factor VIII, leading to mucocutaneous and severe musculoskeletal bleeding.

    • Mucocutaneous Bleeding:

    • Includes gingival bleeding, frequent/prolonged nosebleeds (epistaxis), easy bruising, and prolonged bleeding from minor cuts or venipuncture sites.

    • Hematuria and Gastrointestinal Bleeding:

    • May present as blood in urine or stool.

    • Neonatal Bleeding:

    • Typically mild; significant bleeding at birth is rare unless in severe (Type 3) VWD, where procedures like circumcision may cause hemorrhage.

    • Muscle and Joint Bleeding:

    • Primarily occurs in more severe forms (Type 3) resembling hemarthroses seen in hemophilia.

DIAGNOSIS OF VON WILLEBRAND DISEASE

  • Clinical and family history:

    • Recurrent mucocutaneous bleeding, easy bruising, prolonged bleeding after trauma/surgery, and family history of bleeding disorders.

  • Initial Laboratory Tests:

    • Complete blood count (CBC): Usually normal platelets, rules out thrombocytopenia.

    • Prothrombin time (PT): Typically normal.

    • Activated partial thromboplastin time (aPTT): May be prolonged in moderate to severe cases due to low factor VIII.

    • Bleeding time/platelet function tests: Assess platelet adhesion defects.

    • Specific VWD Assays:

    • VWF Antigen (VWF:Ag): Measures the amount of von Willebrand factor.

    • VWF Activity (ristocetin cofactor assay, VWF:RCo): Evaluates functional ability of VWF to mediate platelet adhesion.

    • Factor VIII Activity: Often reduced in severe forms, especially Type 2 and 3.

    • Genetic testing may confirm diagnosis, particularly in Type 2 variants and Type 3 VWD, and to identify carriers in affected families.

MANAGEMENT OF VON WILLEBRAND DISEASE

  1. Pharmacologic Therapy:

    • Desmopressin (DDAVP): A synthetic vasopressin analog that stimulates release of stored VWF and factor VIII from endothelial cells; effective primarily in Type 1 and some Type 2 variants.

    • VWF-containing factor VIII concentrates: Used in Type 3 VWD or cases unresponsive to DDAVP, including perioperative prophylaxis or treatment of severe bleeding.

    • Adjunctive Hemostatic Agents:

    • Antifibrinolytics (e.g., tranexamic acid, epsilon-aminocaproic acid) for mucosal bleeding, dental procedures, or epistaxis.

  2. Supportive Measures:

    • Local hemostatic interventions: Pressure dressings, topical thrombin, or fibrin sealants for minor bleeding.

    • Avoidance of antiplatelet drugs or NSAIDs, which can exacerbate bleeding.

    • Patient/family education: Recognition of bleeding, prompt treatment, and planning for surgical procedures.

  3. Surgical and Perioperative Management:

    • Preoperative VWF/factor VIII replacement therapy to maintain hemostatic levels during surgery/invasive procedures.

    • Postoperative monitoring for delayed bleeding and continue factor replacement if necessary.

HEMOSTATIC ABNORMALITIES IN LIVER DISEASE

  • Liver disease can lead to multifactorial coagulopathy due to impaired synthesis, dysfunction of clotting proteins, and platelet abnormalities:

    • Biliary Obstruction:

    • Impairs vitamin K absorption, leading to decreased synthesis of vitamin K-dependent clotting factors (II, VII, IX, X).

    • Severe Hepatocellular Disease:

    • Reduces production of factor V, fibrinogen, and plasminogen activator, contributing to bleeding and fibrinolytic imbalance.

    • Dysfibrinogenemia:

    • Synthesis of functionally defective fibrinogen, impairing clot formation.

    • Thrombocytopenia:

    • Due to reduced thrombopoietin production by the diseased liver.

    • Hypersplenism:

    • Secondary to portal hypertension, causing increased platelet sequestration and additional thrombocytopenia.

VITAMIN K DEFICIENCY BLEEDING (VKDB)

  • VKDB refers to bleeding episodes in neonates and young infants due to insufficient vitamin K, typically occurring in the first six months.

  • Vitamin K is a fat-soluble vitamin critical for the γ-carboxylation of glutamic acid residues on several coagulation factors (II, VII, IX, X, and proteins C and S), essential for clot formation.

    • It also contributes to bone metabolism and regulation of calcium homeostasis.

VKDB FEATURE

Feature

Details

Vitamin K Role

Essential for γ-carboxylation of clotting factors II, VII, IX, X, proteins C & S; important in bone metabolism and calcium regulation

Types / Timing

Early VKDB: <24 hours; Classical VKDB: 1-7 days; Late VKDB: 2 weeks–6 months

Common Bleeding Sites

Skin (ecchymoses), gastrointestinal tract, umbilical stump, intracranial

Risk Factors

Exclusive breastfeeding without prophylaxis, maternal medications (e.g., anticonvulsants, antibiotics), malabsorption, liver disease

KEY CLINICAL FEATURES

  • Cutaneous bleeding: Easy bruising, petechiae, or purpura.

  • Mucosal bleeding: Bleeding from gums, nose (epistaxis), or gastrointestinal tract.

  • Umbilical Stump Bleeding: Persistent or delayed bleeding at the umbilical site.

  • Intracranial Hemorrhage: May present with seizures, lethargy, vomiting, or bulging fontanelle; more common in late VKDB.

  • Other bleeding: Hematuria, post-circumcision hemorrhage, or prolonged bleeding after minor trauma.

DIAGNOSIS OF VKDB

  1. Clinical Assessment:

    • Bleeding in a neonate or young infant, typically within the first 6 months of life, especially in breastfed infants without vitamin K prophylaxis.

    • History of maternal medications (e.g., anticonvulsants, antibiotics) or malabsorption disorders.

  2. Laboratory Evaluation:

    • Prolonged prothrombin time (PT) – the earliest and most sensitive indicator.

    • Activated partial thromboplastin time (aPTT) – may also be prolonged in severe cases.

    • Normal platelet count and bleeding time – distinguishes VKDB from platelet disorders.

    • Correction with vitamin K administration – typically normalizes PT/aPTT within 6-24 hours, confirming diagnosis.

  3. Exclusion of Other Disorders:

    • Rule out congenital coagulation factor deficiencies (hemophilia), liver disease, or disseminated intravascular coagulation (DIC).

MANAGEMENT OF VITAMIN K DEFICIENCY BLEEDING (VKDB)

  1. Vitamin K Replacement:

    • Intramuscular (IM) vitamin K1 (phytonadione): Preferred route for both treatment and prophylaxis; rapidly corrects deficiency.

    • Intravenous (IV) or subcutaneous (SC) Vitamin K: Used if IM is contraindicated.

    • Oral Vitamin K: Alternative when IM/IV not feasible, though less reliable for long-term prophylaxis.

  2. Supportive Measures:

    • Blood products: Fresh frozen plasma (FFP) or prothrombin complex concentrate for severe bleeding (especially for intracranial hemorrhage or significant blood loss).

    • Local hemostatic measures: Pressure dressings or topical agents for minor bleeding sites.

  3. Prevention:

    • Routine prophylaxis: IM vitamin K at birth (single dose) is standard to prevent all forms of VKDB.

    • High-risk infants: Those with malabsorption, cholestasis, or liver disease may need additional oral/IM doses.

DISSEMINATED INTRAVASCULAR COAGULATION

  • Disseminated Intravascular Coagulation (DIC) is an acquired syndrome characterized by systemic activation of coagulation pathways, leading to widespread microvascular thrombosis and consumption of platelets and clotting factors.

  • DIC is a secondary complication of various conditions, particularly severe infection, hypoxia, and obstetric complications in neonates.

ETIOLOGY OF DIC

  • Causes Include:

    • Birth Asphyxia and metabolic acidosis

    • Respiratory Distress Syndrome

    • Severe Infection and Neonatal Sepsis

    • Necrotizing Enterocolitis

    • Meconium Aspiration Syndrome

    • Aspiration of Amniotic Fluid

    • CNS injury or intracranial hemorrhage

    • Hypothermia

    • Vascular tumors such as Giant Hemangioma (Kasabach-Merritt phenomenon)

    • Congenital thrombophilic disorders, including homozygous deficiency of protein C or protein S

    • Thrombotic disorders

    • Malignancies (rare in neonates)

CLINICAL FEATURES OF DIC

  • Clinical features:

    • Petechiae, ecchymoses, bleeding from umbilical/venipuncture sites, gastrointestinal or pulmonary hemorrhage, organ dysfunction.

DIAGNOSIS OF DIC

Laboratory Test

Finding

Platelet Count

Decreased

PT

Prolonged

aPTT

Prolonged

Fibrinogen

Decreased

D-dimer / FDP

Increased

Peripheral Smear

Schistocytes

MANAGEMENT OF DIC IN NEWBORNS

  • Primary Step: Identification and treatment of the precipitating condition, as DIC is always secondary.

  • Supportive and Replacement Therapy:

    • Platelet Transfusion:

    • Indicated when platelet count is <50,000/µL with active bleeding; may also be given when <20,000/µL without bleeding.

    • Fresh Frozen Plasma (FFP):

    • Replaces depleted coagulation factors; used when PT and aPTT are significantly prolonged or bleeding is present.

    • Cryoprecipitate:

    • Administered if fibrinogen level <100 mg/dL, provides fibrinogen, factor VIII, and von Willebrand factor.

    • Packed Red Blood Cells:

    • Given to treat significant anemia or blood loss.

THE END

  • HDN is a bleeding disorder in newborns due to immature coagulation systems. Healthy neonates have longer prothrombin and aPTT times but low bleeding risk.

  • Causes:

    • Coagulation Factor Abnormalities: Vitamin K Deficiency, hemophilia, and other inherited disorders.

    • Platelet Abnormalities: Thrombocytopenia and dysfunctional platelets.

    • Fibrinolytic Disturbances: Excessive fibrinolysis prevents stable clot formation.

    • Vascular Disorders: Increased capillary fragility leads to bleeding.

    • Multifactorial Conditions: Metabolic and systemic diseases affecting hemostasis.

  • Classification: Inherited (e.g., Hemophilia A & B) and acquired (e.g., Vitamin K Deficiency Bleeding).

  • Diagnosis: Clinical history, family background, and laboratory tests (CBC, coagulation assays).

  • Management: Focus on bleeding prevention, factor replacement therapy, and supportive measures for severe cases.